Article
Chemistry, Multidisciplinary
Qihang Ding, Ling Mei, Yu Liu, Shan Zhou, Lu Chen, Yuying Liang, Mingle Li, Hui Zhou, Chao Yin, Jong Seung Kim
Summary: Researchers constructed a D-A type-based NIR-II fluorophore with mitochondria targeting, which demonstrated both photothermal effect and photodynamic performance. They further fabricated nanodots with DSPE-mPEG for in vivo experiments, achieving strong NIR-II fluorescence tracing of tumors and impressive NIR-II image-guided photodynamic therapy and photothermal therapy.
CHEMICAL COMMUNICATIONS
(2023)
Review
Nanoscience & Nanotechnology
Jincong Yan, Tian Gao, Zhongzhong Lu, Jingbo Yin, Ye Zhang, Renjun Pei
Summary: Aptamers, short oligonucleotide sequences with selective binding abilities, have shown promise in improving controlled and accurate delivery of photosensitizers into tumor sites for enhanced photodynamic therapy. Modification of aptamers onto PSs or nanocarriers enables specific recognition and binding to tumor cells, resulting in superior therapeutic efficiency. The development of aptamer-targeted platforms for tumor therapy holds potential for synergistic treatment modalities like PDT, photothermal therapy, and chemotherapy.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Article
Oncology
Sheila D. Rustgi, Aaron Oh, Jeong Yun Yang, Dasol Kang, Edward Wolin, Chung Y. Kong, Chin Hur, Michelle K. Kim
Summary: The study shows that initiating SSAs at the time of presentation for patients with metastatic GEP-NETs is not cost-effective. Further clinical studies are needed to determine the optimal timing for initiating these drugs.
Review
Nanoscience & Nanotechnology
Batoul Dhaini, Bibigul Kenzhebayeva, Amina Ben-Mihoub, Mickael Gries, Samir Acherar, Francis Baros, Noemie Thomas, Joel Daouk, Herve Schohn, Tayssir Hamieh, Celine Frochot
Summary: Cancer is the second leading cause of death globally, with treatments including surgery, radiotherapy, chemotherapy, and photodynamic therapy. Using nanoparticles loaded with photosensitizers and coupled to peptides for targeted therapy is a promising approach in cancer treatment.
Review
Nanoscience & Nanotechnology
Rui Wang, Xingshu Li, Juyoung Yoon
Summary: Targeted photodynamic therapy towards subcellular organelles presents a promising strategy for reducing side effects and enhancing therapeutic efficacy, providing implementable strategies for precision medicine in the future.
ACS APPLIED MATERIALS & INTERFACES
(2021)
Article
Chemistry, Multidisciplinary
Xue-Liang Liu, Xiao Dong, Si-Cong Yang, Xing Lai, Hai-Jun Liu, Yuhao Gao, Hai-Yi Feng, Mao-Hua Zhu, Yihang Yuan, Qin Lu, Jonathan F. Lovell, Hong-Zhuan Chen, Chao Fang
Summary: Nano-Pt loaded liposomal system enhances photodynamic therapy and chemotherapy in cancer treatment by increasing oxygen supply and releasing nanoparticles for better penetration, leading to inhibited tumor growth and extended survival without toxicity in animal models.
Article
Materials Science, Multidisciplinary
Xiaokai Chen, Xiaodong Zhang, Yinglong Wu, Yun Chen, Yi Guo, Deblin Jana, Dongdong Wang, Wei Yuan, Yanli Zhao
Summary: In this study, a multifunctional nanoscavenger was designed to clear tumor extracellular matrix, improve tumor hypoxia, and enhance photodynamic and immune therapies. This strategy provides a solution to overcome the suppressive tumor microenvironment.
Article
Materials Science, Multidisciplinary
Tanveer A. Tabish, Mian Zahid Hussain, Roland A. Fischer, Angela Casini
Summary: Much progress has been made in subcellular targeted therapy of cancer by attacking disease cell's mitochondria. Mitochondrial dysfunction controls key metabolic changes and is related to tumor invasion, proliferation, tumorigenesis, and metastasis. Supramolecular metal-organic frameworks (MOFs) can be targeted to the tumor's mitochondria selectively and disrupt cancer cells' metabolic processes. Mitochondria-targeted MOFs (mitoMOFs) have the potential to revolutionize targeted therapy and improve therapeutic outcomes with minimal side-effects.
Article
Engineering, Biomedical
Xiangyu Deng, Wenbo Yang, Zengwu Shao, Yanli Zhao
Summary: The research utilizes genetically modified live attenuated bacteria in combination with Chlorin e6 (Ce6) for photodynamic therapy, achieving precise tumor inhibition.
Article
Biochemistry & Molecular Biology
Halil I. Ciftci, Mohamed O. Radwan, Belgin Sever, Ahmed K. Hamdy, Safiye Emirdag, N. Gokce Ulusoy, Ece Sozer, Mustafa Can, Nurettin Yayli, Norie Araki, Hiroshi Tateishi, Masami Otsuka, Mikako Fujita, Mehlika Dilek Altintop
Summary: Compound 10 has been identified as the most potent anti-glioma agent against human glioblastoma cells, and it exerts selective antitumor action towards leukemic T-cells.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Chemistry, Multidisciplinary
Lan Yang, Huijie Ma, Ye Liu, Rumeng Cao, Shaofeng Chen, Jiajia Wang, Ling Xiang, Jiumeng Zhang, Xuli Feng, Chenhui Wang
Summary: A nucleus-targeted enzyme prodrug nanocomposite, assembled from β-cyclodextrin-lysine (CL), catalase (CAT), Pt(iv) and chlorin e6 (Ce6), was developed for self-augmenting cascade photo-chemo therapy of tumors. It can effectively transport through the cytoplasm and accumulate in the nucleus, thereby significantly inhibiting tumor growth and lung metastasis.
CHEMICAL COMMUNICATIONS
(2023)
Article
Chemistry, Inorganic & Nuclear
Ruixue Cui, Jing Shi, Zhiliang Liu
Summary: The study introduces a novel drug delivery system CDZH, capable of targeted release of chemotherapy drugs and H2O2 supply in acidic tumor microenvironment, showing excellent chemo/chemodynamic synergistic therapy capability.
DALTON TRANSACTIONS
(2021)
Review
Endocrinology & Metabolism
Yuheng Hu, Zeng Ye, Fei Wang, Yi Qin, Xiaowu Xu, Xianjun Yu, Shunrong Ji
Summary: SSTRs have significant clinical significance in pNETs, serving as important targets for diagnosis and treatment, but further research is needed.
FRONTIERS IN ENDOCRINOLOGY
(2021)
Article
Chemistry, Multidisciplinary
Jiangsheng Xu, James G. Shamul, Elyahb Allie Kwizera, Xiaoming He
Summary: Mitochondria are critical organelles for producing energy in cells and can be targeted for cancer therapy. Mitochondria-targeting nanotechnologies have shown high efficacy for cancer treatment both in vitro and in vivo, and can be intelligently designed based on the characteristics of the tumor microenvironment.
Article
Biochemistry & Molecular Biology
Alex Vasilev, Roba Sofi, Stuart J. Smith, Ruman Rahman, Anja G. Teschemacher, Sergey Kasparov
Summary: One of the most challenging problems in treating glioblastoma (GBM) is its highly infiltrative nature. Researchers have found that using tetramethylrhodamine methyl ester (TMRM) as a photosensitizer in combination with photodynamic therapy (PDT) can target GBM cells, inducing mitochondrial damage and cell death, making it a potential direction for clinical translation.
Article
Medicine, General & Internal
Alessandro Prete, Anuradhaa Subramanian, Irina Bancos, Vasileios Chortis, Stylianos Tsagarakis, Katharina Lang, Magdalena Macech, Danae A. Delivanis, Ivana D. Pupovac, Giuseppe Reimondo, Ljiljana Marina, Timo Deutschbein, Maria Balomenaki, Michael W. O'Reilly, Lorna C. Gilligan, Carl Jenkinson, Tomasz Bednarczuk, Catherine D. Zhang, Tina Dusek, Aristidis Diamantopoulos, Miriam Asia, Agnieszka Kondracka, Dingfeng Li, Jimmy R. Masjkur, Marcus Quinkler, Grethe A. Ueland, M. Conall Dennedy, Felix Beuschlein, Antoine Tabarin, Martin Fassnacht, Miomira Ivovic, Massimo Terzolo, Darko Kastelan, William F. Young, Konstantinos N. Manolopoulos, Urszula Ambroziak, Dimitra A. Vassiliadi, Angela E. Taylor, Alice J. Sitch, Krishnarajah Nirantharakumar, Wiebke Arlt
Summary: Patients with mild autonomous cortisol secretion (MACS), especially MACS-2 and CS, have a higher prevalence and severity of hypertension and type 2 diabetes. MACS predominantly affects women and regular assessment for cardiometabolic diseases is warranted.
ANNALS OF INTERNAL MEDICINE
(2022)
Article
Endocrinology & Metabolism
Anela Blazevic, Anand M. Iyer, Marie-Louise F. Van Velthuysen, Johannes Hofland, Lindsey Oudijk, Wouter W. de Herder, Leo J. Hofland, Richard A. Feelders
Summary: Small-intestinal neuroendocrine tumors (SI-NETs) have a higher prevalence and worse prognosis in male patients. This study found that mesenteric metastasis and fibrosis were more common in men than women. The risk of mesenteric metastasis in women increased around menopause. The expression of estrogen receptor alpha and androgen receptor was observed in primary tumors and mesenteric metastases.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2022)
Article
Pharmacology & Pharmacy
Maria J. Klomp, Leo J. Hofland, Lilian van den Brink, Peter M. van Koetsveld, Fadime Dogan, Corrina M. A. de Ridder, Debra C. Stuurman, Marian C. Clahsen-van Groningen, Marion de Jong, Simone U. Dalm
Summary: The study aimed to enhance the expression of somatostatin type-2 receptors (SSTR2) using valproic acid (VPA) for peptide receptor radionuclide therapy (PRRT). VPA significantly increased SSTR2 expression in vitro, but in vivo, increased tumor uptake of [Lu-177]Lu-DOTATATE was not caused by SSTR2 upregulation but rather by other mechanisms such as increased radiotracer circulation time and renal toxicity.
Article
Endocrinology & Metabolism
Anela Blazevic, Anand M. Iyer, Marie-Louise F. van Velthuysen, Johannes Hofland, Peter M. van Koestveld, Gaston J. H. Franssen, Richard A. Feelders, Marina Zajec, Theo M. Luider, Wouter W. de Herder, Leo J. Hofland
Summary: This study found a decreased expression of tryptophan and serotonin-metabolizing enzymes in the stroma of patients with MF. This may explain the increased profibrotic potential of serotonin and the variability in the development of fibrotic complications associated with SI-NETs.
ENDOCRINE CONNECTIONS
(2022)
Article
Biochemistry & Molecular Biology
Amber Blaauboer, Peter M. van Koetsveld, Dana A. M. Mustafa, Jasper Dumas, Fadime Dogan, Suzanne van Zwienen, Casper H. J. van Eijck, Leo J. Hofland
Summary: This study investigates the chemosensitizing effect of different epi-drugs when combined with gemcitabine in pancreatic cancer. The results show that VPA combined with gemcitabine significantly reduces tumor size and activates the immune system. These findings provide a strong rationale for the application of this combination therapy in pancreatic cancer patients.
Article
Oncology
Amber Blaauboer, Peter M. Van Koetsveld, Dana A. M. Mustafa, Jasper Dumas, Fadime Dogan, Suzanne Van Zwienen, Casper H. J. Van Eijck, Leo J. Hofland
Summary: In this study, the antitumor effect of IFN-beta combined with gemcitabine in pancreatic cancer was investigated. It was found that the combination treatment enhanced the antitumor effect and had immunomodulatory effects. However, in mouse experiments, the change in tumor size with the combination treatment was not significant.
INTERNATIONAL JOURNAL OF ONCOLOGY
(2022)
Article
Oncology
Thomas Cuny, Peter M. van Koetsveld, Gregoire Mondielli, Fadime Dogan, Wouter W. de Herder, Anne Barlier, Leo J. Hofland
Summary: The treatment of pancreatic neuroendocrine neoplasms (PNEN) is challenging due to metastasis at diagnosis and resistance to treatment in some patients. This study explores the role of stromal fibroblasts in the growth of PNEN and their response to the mTOR inhibitor everolimus. The findings suggest that fibroblasts in the tumor microenvironment of PNEN could be a promising therapeutic target.
Article
Oncology
Julie Refardt, Maria J. Klomp, Peter M. van Koetsveld, Fadime Dogan, Mark Konijnenberg, Tessa Brabander, Richard A. Feelders, Wouter W. de Herder, Leo J. Hofland, Johannes Hofland
CLINICAL AND TRANSLATIONAL MEDICINE
(2022)
Article
Endocrinology & Metabolism
Claudia Campana, Peter M. van Koetsveld, Richard A. Feelders, Wouter W. de Herder, Anand M. Iyer, Marie-Louise F. van Velthuysen, Marije J. Veenstra, Elisabeth S. R. van den Dungen, Sanne E. Franck, Diego Ferone, Federico Gatto, Leo J. Hofland
Summary: The aim of this study was to develop an open-source and reproducible digital quantitative analysis method for evaluating somatostatin receptor subtype 2a staining in pancreatic neuroendocrine tumors and growth hormone-secreting pituitary adenomas. The results showed that this method had a strong correlation with the widely used semi-quantitative immunoreactivity score and could also evaluate the biochemical response to somatostatin receptor ligands.
EUROPEAN JOURNAL OF ENDOCRINOLOGY
(2022)
Article
Hematology
Sena Kim, Sora Lim, Boram Kim, Julie Ritchey, Kiran Vij, Julie Prior, Lynne Marsala, Alyssa Stoner, Feng Gao, Samuel Achilefu, Matthew L. Cooper, John F. DiPersio, Jaebok Choi
Summary: By blocking the IFNGR signaling pathway, S100A9 is upregulated in T cells and acts as a novel suppressor of graft-versus-host disease (GVHD) while preserving graft-versus-leukemia (GVL) effects. In both mouse models of allo-HSCT and xenogeneic human peripheral blood mononuclear cell transplantation, overexpression of S100A9 or administration of anti-IFNGR antibody improved GVHD without compromising GVL and reduced T-cell trafficking to GVHD target organs.
Article
Endocrinology & Metabolism
Federico Gatto, Richard A. Feelders, Peter M. van Koetsveld, Fadime Dogan, Sebastian J. C. M. M. Neggers, Aart-Jan van der Lelij, Jessica Amaru, Diego Ferone, Leo J. Hofland
Summary: Cabergoline (CAB) is an off-label medical therapy for acromegaly, but it is overshadowed by first-generation somatostatin receptor ligands like octreotide (OCT). In this study, OCT was found to be slightly more effective than CAB in inhibiting growth hormone (GH) secretion in vitro. Additionally, the response to CAB treatment was shown to be better in GH/prolactin (PRL) co-secreting tumors.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
(2023)
Article
Endocrinology & Metabolism
Eva M. G. Viho, Jan Kroon, Richard A. Feelders, Rene Houtman, Elisabeth S. R. van den Dungen, Alberto M. Pereira, Hazel J. Hunt, Leo J. Hofland, Onno C. Meijer
Summary: Glucocorticoid stress hormones are essential for physiology and exert numerous actions via binding to the glucocorticoid receptor (GR). Relacorilant is a selective GR antagonist being evaluated for the treatment of endogenous Cushing's syndrome. This study compared the effects of relacorilant and the non-selective antagonist mifepristone, showing that relacorilant has potent antagonistic effects on GR signaling and prevents anti-inflammatory effects of glucocorticoids.
JOURNAL OF ENDOCRINOLOGY
(2023)
Article
Oncology
Anela Blazevic, Anand M. Iyer, Marie-Louise F. van Velthuysen, Johannes Hofland, Gaston J. H. Franssen, Richard A. Feelders, Marina Zajec, Theo M. Luider, Wouter W. de Herder, Leo J. Hofland
Summary: Mesenteric metastases in small intestinal neuroendocrine tumors (SI-NETs) are associated with mesenteric fibrosis (MF). Proteomics-based analysis found differential protein abundance primarily in the stromal compartment of mesenteric metastases of SI-NET patients with MF. The differentially abundant proteins included collagen and proteoglycans associated with profibrotic extracellular matrix dysregulation and signaling pathways. COL12A1 and C9 were confirmed to have significantly higher expression in MF mesenteric metastases. This study provides insights into new signaling pathways involved in MF development.
ENDOCRINE-RELATED CANCER
(2023)
Article
Endocrinology & Metabolism
Maria J. Klomp, Julie Refardt, Peter M. van Koetsveld, Claudia Campana, Simone U. Dalm, Fadime Dogan, Marie-Louise F. van Velthuysen, Richard A. Feelders, Wouter W. de Herder, Johannes Hofland, Leo J. Hofland
Summary: This study found that DNA methylation and histone modifications are associated with SST2 expression in SI-NETs. DNA methylation levels and H3K27me3 levels were lower in SI-NETs compared to normal tissue, and there was a negative correlation between SST2 mRNA expression level and DNA methylation. However, the role of histone modifications in SI-NETs remains unclear.
FRONTIERS IN ENDOCRINOLOGY
(2023)
Article
Medicine, Research & Experimental
Maria J. Klomp, Lilian van den Brink, Peter M. van Koetsveld, Corrina M. A. de Ridder, Debra C. Stuurman, Clemens W. G. M. Lowik, Leo J. Hofland, Simone U. Dalm
Summary: In vitro experiments showed that HDAC inhibitors had the desired effects. However, there was no significant increase in tumoral DOTA-TATE uptake after HDAC inhibitor treatment in NCI-H69 tumor-bearing animals. The expression levels of tumoral SSTR2 mRNA and/or protein were significantly upregulated after treatment with certain inhibitors. There was a significant inverse correlation between HDAC3 and SSTR2 expression in the studied cell lines.
